Ruthenium Pyrazole Complexes as Potential Anticancer Agents
Abstract
Ru complexes are less harmful because that they are tumor selective, activated only under redox conditions, and biologically more gentle meaning these new drugs will not adversely affect healthy tissue as much as do classic platinum analogues. Ruthenium based complexes are considered encouraging different approach to existing chemotherapeutic agents. Hence, the present study is geared towards the synthesis and structural characterization of novel Ru (II) & Ru (III) complexes with pyrazole-based ligands. A variety of seven ruthenium Pyrazole complexes were synthesized by using cis-RuCl₂(DMSO)₄, cis-RuCl₂(TMSO)₄, and mer-RuCl3(DMSO)3 with pyrazole ligands through refluxing, crystallization, filtration and finally vacuum drying. These seven novel ruthenium-pyrazole complexes [dichloro-(tris(dimethyl sulfoxide))-(4 methyl-1H-pyrazole)-ruthenium (II)], [dichloro-(tris(dimethyl sulfoxide))-(3-phenyl-1H pyrazole)-ruthenium(II)], [dichloro-(tris(tetramethyl sulfoxide))-(3-phenyl-1H-pyrazole) ruthenium (II)], [trichloro-(dimethyl sulfoxide)-bis(4-methyl-1H-pyrazole)-ruthenium (III)], [trichloro-(bis(dimethyl sulfoxide))-( 3-phenyl-1H-pyrazole)-ruthenium (III)], [trichloro (bis(dimethyl sulfoxide))-(4-nitro-1H-pyrazole)-ruthenium (III)], [trichloro-(bis(dimethyl sulfoxide))-(3-amino-5-methylpyrazole)-ruthenium (III)] have been characterized by use of a combination of spectroscopy; such as UV-visible, IR, and NMR, and X-ray crystallography. Cell viability test has been done for two complexes, from these two complexes one complex [trichloro-(dimethyl sulfoxide)-bis(4-methyl-1H-pyrazole)-ruthenium (III) found active (IC₅₀ of 15.11 µM) against lung cancer cell line A549.